Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model.
Ontology highlight
ABSTRACT: Osteosarcoma (OS) is the most common primary malignant bone tumor, and the current standard of care for OS includes neoadjuvant chemotherapy, followed by an R0 surgical resection of the primary tumor, and then postsurgical adjuvant chemotherapy. Bone reconstruction following OS resection is particularly challenging due to the size of the bone voids and because patients are treated with adjuvant and neoadjuvant systemic chemotherapy, which theoretically could impact bone formation. We hypothesized that an osteogenic material could be used in order to induce bone regeneration when adjuvant or neoadjuvant chemotherapy is given. We utilized a biomimetic, biodegradable magnesium-doped hydroxyapatite/type I collagen composite material (MHA/Coll) to promote bone regeneration in the presence of sy
SUBMITTER: Brozovich AA
PROVIDER: S-EPMC10936525 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA